Last reviewed 2026-04-22 · How we verify

DE-111 ophthalmic solution

DE-111 is a selective dopamine D1 receptor agonist that enhances aqueous humor outflow to reduce intraocular pressure in glaucoma.

DE-111 is a selective dopamine D1 receptor agonist that enhances aqueous humor outflow to reduce intraocular pressure in glaucoma. Used for Glaucoma or ocular hypertension.

At a glance

Mechanism of action

DE-111 works by stimulating dopamine D1 receptors in the eye, which promotes increased drainage of fluid (aqueous humor) through the trabecular meshwork and uveoscleral pathways. This enhanced outflow reduces intraocular pressure, the primary pathogenic factor in glaucoma. The dopamine D1 agonist mechanism represents a novel approach distinct from traditional prostaglandin analogs, beta-blockers, or carbonic anhydrase inhibitors.

Approved indications

• Glaucoma or ocular hypertension

Common side effects

• Conjunctival hyperemia
• Eye irritation
• Blurred vision

Key clinical trials

• DE-111 Against Timolol Ophthalmic Solution 0.5% (PHASE3)
• DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension (PHASE3)
• DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5% (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• DE-111 ophthalmic solution CI brief — competitive landscape report
• DE-111 ophthalmic solution updates RSS · CI watch RSS
• Santen Pharmaceutical Co., Ltd. portfolio CI